Vazamide SR

Indapamide.

Each sustained-release tablet contains indapamide 1.5 mg.

Pharmacology: Pharmacokinetics: Indapamide is rapidly and completely absorbed from the gastro-intestinal tract. Elimination is biphasic with a half-life in whole blood of about 14 hours. Indapamide is strongly bound to red blood cells. It is extremely metabolised. About 60 to 70% of the dose has been reported to be excreted in the urine; only about 5 to 7% is excreted unchanged. About 16 to 23% of the administrated dose is excreted haemodialysis but does not accumulate in patients with impaired renal function.

Indapamide is indicated in the management of mild to moderate hypertension and also for oedema, including that associated with heart failure.

One tablet once daily, or as directed by the physician.

Indapamide is contraindicated in:
Individuals who are hypersensitive to Indapamide or other sulphonamide type medications.
Severe hepatic insufficiency.
Severe renal failure with creatinine clearance.

Electrolyte changes observed with Indapamide become more prominent at doses above 1.5 mg sustained release tablet/day. The daily maximum recommended dose of Indapamide is 1.5 mg administered as one sustained release tablet.

Patients receiving indapamide should be monitored for signs and symptoms of fluid or electrolyte imbalance; namely hyponatremia, hypochloraemia and hypokalaemia. Blood urea nitrogen and uric acid should also be assessed during therapy. The signs of electrolyte imbalance are dryness of mouth, thirst, weakness, lethargy, drowsiness, restlessness, muscle pains or cramps, muscle fatigue, hypotension, oliguria, gastrointestinal disturbances such as nausea and vomiting, tachycardia, and ECG changes.

In general, most adverse effects are mild and transient with the most frequently reported being giddiness, diarrhoea, headache, anorexia, gastric irritation, nausea, vomiting, abdominal pain usually occurring within the first month of treatment. Electrolyte imbalances including hypochloraemic alkalosis, hyponatraemia, hypokalaemia and hyperuricaemia; hypersensitivity reactions which include skin rashes, pulmonary oedema, pneumonitis, cholestatic jaundice, pancreatitis and blood dyscrasias including thrombocytopenia and less frequently granulocytopenia, leucopenia, aplastic anemia and haemolytic anaemia have been reported. Serum potassium should be monitored in patients with a history of gout, who should continue to receive appropriate treatment.
"For suspected adverse drug reaction, report to FDA: www.fda.gov.ph or to TORRENT: www.torrentpharma.com". Patient to seek medical attention immediately at the first sign of any adverse drug reaction shall appear.

Store at temperatures not exceeding 30°C.

Diuretics

C03BA11 - indapamide ; Belongs to the class of low-ceiling sulfonamide diuretics.

Rx